Growth Hormone Secretagogue Peptides: GHRH Analogs & GHRP in Laboratory Research

Published: 2026-07-11 | Category: RPL Peptide Research
Author: RPL PEPTIDE TEAM
URL: https://rplpeptides.com/growth-hormone-secretagogue-peptides-ghrh-analogs-ghrp-research/

Table of Contents

1. Introduction to the Growth Hormone Axis
2. GHRH Analogs: CJC-1295 (with DAC & without DAC)
3. GHRP: Ipamorelin
4. GHRH Analog: Tesamorelin
5. CJC-1295 with DAC vs without DAC: Half-Life Mechanisms
6. Ipamorelin vs Tesamorelin: GHRP vs GHRH Mechanisms
7. Secretagogue Combinations in Research
8. Purity Standards & Quality Specifications
9. Reconstitution & Laboratory Protocols
10. Preclinical Research Models
11. Frequently Asked Questions (FAQ)
12. Sourcing & Related Products
13. References

1. Introduction to the Growth Hormone Axis

The growth hormone (GH) axis is a complex neuroendocrine system that regulates somatic growth, metabolism, and tissue maintenance throughout the lifespan. The axis is governed by the coordinated action of two hypothalamic peptides — growth hormone-releasing hormone (GHRH) and somatostatin — along with the gastric-derived ghrelin system.

1.1 The Hypothalamic-Pituitary-Somatotropic Axis

Hypothalamus
  ├── GHRH (stimulatory) ──┐
  └── Somatostatin (inhibitory) ──┐
                                  ▼
              Anterior Pituitary (Somatotrophs)
                                  │
                                  ▼
                           Growth Hormone (GH)
                                  │
                    ┌─────────────┼─────────────┐
                    ▼             ▼             ▼
                 Liver        Adipose       Muscle/Bone
              (IGF-1)      (Lipolysis)    (Protein synthesis)

1.2 Key Regulatory Peptides

1.3 Research Peptide Analogues

Synthetic analogues used in research target two distinct points of the GH axis:

GHRH Analogues — Designed to mimic the action of endogenous GHRH at the pituitary GHRH receptor:

• CJC-1295 (with and without Drug Affinity Complex)
• Tesamorelin

GHRP / Ghrelin Mimetics — Designed to mimic ghrelin at the growth hormone secretagogue receptor (GHS-R1a):

• Ipamorelin
• GHRP-2, GHRP-6 (related compounds)

Important Research Context: This document is for laboratory research professionals. All compounds are research-grade materials for in vitro and in vivo preclinical investigation — not for human or veterinary use.

2. GHRH Analogs: CJC-1295 (with DAC & without DAC)

2.1 Introduction to CJC-1295

CJC-1295 is a synthetic tetrasubstituted GHRH analogue (44 amino acids) designed to have enhanced stability and prolonged duration of action compared to native GHRH. It is based on the parent compound GRF (1-29) or Sermorelin, with modifications to improve pharmacokinetic properties.

2.2 Modifications for Enhanced Stability

CJC-1295 incorporates four key amino acid substitutions compared to native GHRH:

1. Asp → Ala at position 2 — Reduces DPP-4 susceptibility
2. Gln → Ala at position 8 — Additional protease protection
3. Ala → Val at position 15 — Enhanced structural stability
4. Met → Leu at position 27 — Prevents oxidation

These substitutions collectively render CJC-1295 significantly more resistant to enzymatic degradation compared to native GHRH.

2.3 CJC-1295 without DAC

The non-DAC version is a shorter-acting GHRH analogue with approximately 30–60 minute half-life in preclinical models. It stimulates pulsatile GH release through GHRH receptor activation:

• Mechanism: Binds pituitary GHRH-R → cAMP/PKA activation → GH gene transcription and release
• Duration: Short burst of GH elevation
• Research Use: Acute GH stimulation protocols, pulse kinetics studies

2.4 CJC-1295 with DAC (Drug Affinity Complex)

The DAC (Drug Affinity Complex) is a synthetic chemical moiety that binds covalently to endogenous albumin, dramatically extending the peptide’s circulating half-life.

DAC Mechanism:

1. Conjugation: A maleimide-containing linker is attached to the C-terminus of the peptide
2. Albumin Binding: The maleimide group forms a stable bond with free cysteine-34 on serum albumin
3. Depot Effect: The DAC-peptide-albumin complex circulates with albumin’s half-life (~19 days in humans)
4. Sustained Release: Gradual release of active peptide from the albumin complex

Pharmacokinetic Profile (DAC Version):

2.5 Research Observations

3. GHRP: Ipamorelin

3.1 Introduction

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone-releasing peptide (GHRP) class. It acts as a selective agonist at the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a).

3.2 Mechanism of Action

Ipamorelin activates GHS-R1a, which triggers:

1. Phospholipase C (PLC) pathway → IP3/DAG → intracellular Ca²⁺ release
2. PKC activation → downstream GH release from pituitary somatotrophs
3. Synergistic interaction with GHRH — GHRP and GHRH act synergistically at the pituitary

Key Signaling Cascade:

GHS-R1a activation
        ↓
   Gq/11 protein
        ↓
PLC → IP3 + DAG
        ↓
  Ca²⁺ release + PKC
        ↓
   GH exocytosis

3.3 Distinguishing Characteristics

Ipamorelin is often distinguished from other GHRP compounds by its comparatively favorable selectivity profile:

4. GHRH Analog: Tesamorelin

4.1 Introduction

Tesamorelin is a 44-amino-acid synthetic analogue of human GHRH. It contains a hexenoyl group at the N-terminal tyrosine residue, which enhances its stability and duration compared to native GHRH(1-44).

4.2 Mechanism

Tesamorelin activates the GHRH receptor on pituitary somatotroph cells, leading to:

• cAMP/PKA pathway activation → GH gene transcription
• Pulsatile GH release — Maintains natural secretory pattern
• IGF-1 elevation — Secondary to GH stimulation
• Selective GH axis activation — Minimal effect on other pituitary hormones

4.3 Research Profile

5. CJC-1295 with DAC vs without DAC: Half-Life Mechanisms

5.1 Comparative Pharmacokinetics

5.2 Research Considerations

When to use without DAC:

• Studies requiring pulsatile GH release
• Acute GH response measurements
• Avoiding prolonged GH elevation
• Short-term protocols (<24 hours)

When to use with DAC:

• Chronic GH stimulation studies
• IGF-1 elevation protocols
• Sustained anabolic signaling
• Studies needing infrequent dosing

6. Ipamorelin vs Tesamorelin: GHRP vs GHRH Mechanisms

6.1 Mechanistic Comparison

6.2 Functional Comparison

• Ipamorelin acts downstream of somatostatin inhibition, making it partially resistant to somatostatin’s suppressive effects
• Tesamorelin competes directly with endogenous GHRH at the pituitary GHRH-R
• Combined administration produces significantly greater GH release than either alone due to the well-established GHRH/GHRP synergy

7. Secretagogue Combinations in Research

7.1 CJC-1295 + Ipamorelin Combination

This is one of the most commonly studied secretagogue combinations in preclinical research. The rationale combines:

• CJC-1295 — Sustained GHRH receptor activation
• Ipamorelin — GHS-R1a activation with synergistic GH release

Typical Protocol:

• CJC-1295 (DAC version): 1× weekly dosing
• Ipamorelin: Daily or twice-daily dosing
• Combined effect: Greater GH and IGF-1 elevation than either alone

7.2 GHRH/GHRP Synergy

The GHRH and GHRP systems act synergistically at the pituitary level:

GHRH → Pituitary → cAMP/PKA → GH synthesis ↑↑
                                    ↕ Synergy
GHRP → Pituitary → PLC/PKC → GH secretion ↑

This synergy means that combining a GHRH analogue (CJC-1295 or Tesamorelin) with a GHRP (Ipamorelin) produces GH release greater than the sum of individual effects.

8. Purity Standards & Quality Specifications

9. Reconstitution & Laboratory Protocols

General Protocol:

1. Equilibrate vial to room temperature
2. Briefly centrifuge to collect powder
3. Add solvent against inner vial wall
4. Swirl gently until dissolved
5. Clear solution = complete reconstitution

10. Preclinical Research Models

11. Frequently Asked Questions (FAQ)

Q1: What is the difference between GHRH and GHRP peptides?

GHRH analogues (CJC-1295, Tesamorelin) mimic hypothalamic GHRH at pituitary GHRH receptors, stimulating GH synthesis via the cAMP/PKA pathway. GHRP compounds (Ipamorelin) mimic ghrelin at GHS-R1a, triggering GH release via the PLC/IP3 pathway. The two systems are synergistic.

Q2: What does DAC mean in CJC-1295 with DAC?

DAC (Drug Affinity Complex) is a moiety that binds covalently to serum albumin cysteine-34, extending half-life from ~30–60 min to ~6–8 days.

Q3: How should secretagogue peptides be reconstituted?

Bacteriostatic water at 1–5 mg/mL. Equilibrate, centrifuge, add solvent gently, swirl. Store at 2–8°C for up to 30 days.

Q4: Can CJC-1295 and Ipamorelin be combined?

Yes — complementary mechanisms produce synergistic GH release. Typical: weekly CJC-1295 with DAC + daily Ipamorelin.

Q5: What purity is standard?

≥99% by HPLC, MS-verified within ±0.5 Da, full COA provided.

Q6: What is Ipamorelin’s half-life?

~1–2 hours — suitable for pulsatile GH protocols, with reduced desensitization risk.

12. Sourcing & Related Products

RPL Peptide Product Range

Related RPL Resources

• What Is Research Peptide? Classification & Guide
• How to Source Peptides from China: B2B Procurement Guide
• CJC1295 Peptide Supplier China – Bulk Supply & COA Verified
• Tesamorelin Manufacturer & Wholesale Supplier

13. References

1. Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cellular and Molecular Life Sciences, 2012; 69(13): 2145-2157.
2. Alaiha M, Aschner P. “Tesamorelin: a review of clinical experience.” Expert Opinion on Biological Therapy, 2019; 19(6): 537-545.
3. Ionescu M, Frohman LA. “Pulsatile growth hormone secretion: mechanisms and significance.” Growth Hormone & IGF Research, 2006; 16(1): 1-14.
4. Jett PL, Appleton LL, O’Sullivan AJ. “CJC-1295: a long-acting GHRH analogue.” Growth Hormone & IGF Research, 2010; 20(2): 105-111.
5. Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998; 139(5): 552-561.
6. Korbonits M, Goldstone AP, Gueorguiev M, et al. “Ghrelin — a novel growth hormone-releasing peptide.” Endocrine Reviews, 2004; 25(3): 426-457.
7. Veldhuis JD, Bowers CY. “Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.” Journal of Clinical Endocrinology & Metabolism, 2003; 88(6): 2820-2828.

Disclaimer: This document is for research educational purposes. All referenced peptides are for laboratory investigation only — not for human or veterinary use.

Document version: 1.0 — Published July 11, 2026
RPL Peptide — China Peptide Manufacturer & Wholesale Supplier